Literature DB >> 4009408

Pharmacokinetics of spironolactone and potassium canrenoate in humans.

K Kojima, K Yamamoto, H Fujioka, H Kaneko.   

Abstract

Plasma concentrations and urinary excretion of canrenone (III), canrenoic acid (IV) and canrenoic acid glucuronide (V) were determined by means of high performance liquid chromatography (HPLC) and fluorometry after oral administration of spironolactone (I) and potassium canrenoate (II) to human subjects. Comparison of both assays for III in plasma as well as in urine after administration of I showed marked differences. Plasma concentrations of III were significantly higher after administration of II than I, Cmax and AUC from II being 3--5 times larger than those from I by means of HPLC assay, while the fluorometrically determined values for III in plasma after administration of I and II did not differ as much from each other. On the other hand, in contrast to plasma, the amount of III excreted in urine after administration of I was much larger than that after II, i.e. 3--4 times greater by means of HPLC and over 10 times greater by means of fluorometry. These results strongly suggest that precursors of III are formed which have a higher renal clearance than that for III alone after oral administration of I. Considering the relative biological potency ratio of I and II, it is presumed that their pharmacological activities may relate to the urinary excretion of III. Plasma concentrations of IV were definitely higher after administration of II compared to those after I. Canrenoic acid (IV) was excreted mainly as glucuronide (V) in urine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4009408     DOI: 10.1248/bpb1978.8.161

Source DB:  PubMed          Journal:  J Pharmacobiodyn        ISSN: 0386-846X


  6 in total

1.  Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.

Authors:  Amitava Dasgupta; Myrtle J Johnson; Tamal K Sengupta
Journal:  J Clin Lab Anal       Date:  2012-05       Impact factor: 2.352

2.  Effects of the aldosterone receptor antagonist potassium canrenoate on renal blood flow and urinary output during prolonged increased intraabdominal pressure (IAP) in pigs.

Authors:  F F Gudmundsson; A Viste; O L Myking; K Grong; K Svanes
Journal:  Surg Endosc       Date:  2004-08-26       Impact factor: 4.584

3.  Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate.

Authors:  D Armanini; C Scaroni; M J Mattarello; C Fiore; N Albiger; P Sartorato
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

4.  A new enzyme-linked chemiluminescent immunosorbent digoxin assay is virtually free from interference of spironolactone, potassium canrenoate, and their common metabolite canrenone.

Authors:  Amitava Dasgupta; Edward Kang; Pradip Datta
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

5.  Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.

Authors:  Amitava Dasgupta; Myrtle J Johnson
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

6.  Improved bioavailability from a spironolactone beta-cyclodextrin complex.

Authors:  N T Yusuff; P York; H Chrystyn; P N Bramley; R D Swallow; B R Tuladhar; M S Losowsky
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.